{"gene":"TGFBR3","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1993,"finding":"Betaglycan (TGFBR3) presents TGF-β directly to the type II signaling receptor kinase subunit, forming a high-affinity ternary complex. Membrane betaglycan increases TGF-β binding to the signaling receptor and eliminates biological differences between TGF-β isoforms.","method":"Receptor binding assays, crosslinking, cell-based functional assays with overexpression","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays, functional overexpression, replicated across multiple labs subsequently","pmids":["8391934"],"is_preprint":false},{"year":1991,"finding":"Betaglycan is a membrane-anchored proteoglycan with an extracellular domain bearing GAG attachment sites; its transmembrane and cytoplasmic domains share homology with endoglin. The ectodomain can be shed as a soluble proteoglycan. GAG chains are dispensable for TGF-β binding to the core protein.","method":"cDNA cloning, sequencing, domain analysis, biochemical characterization","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — primary structure determination with functional validation; foundational structural paper replicated widely","pmids":["1657406"],"is_preprint":false},{"year":1994,"finding":"TGF-β binds to the NH2-terminal endoglin-related region of betaglycan. GAG attachment sites are Ser535 and Ser546; their mutation prevents GAG attachment but does not affect TGF-β binding or presentation. Membrane anchorage is required for TGF-β presentation to receptor II. Soluble betaglycan acts as a potent inhibitor (antagonist) of TGF-β binding to membrane receptors, particularly TGF-β2.","method":"Site-directed mutagenesis, deletion mutant analysis, binding assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis with multiple deletion constructs, functional assays; foundational mechanism paper","pmids":["8106553"],"is_preprint":false},{"year":2000,"finding":"Betaglycan functions as an inhibin co-receptor with ActRII. Betaglycan binds inhibin with high affinity, enhances inhibin binding in cells co-expressing ActRII and betaglycan, and forms crosslinked ternary complexes with recombinant and endogenous betaglycan and ActRII. Betaglycan confers inhibin sensitivity to otherwise poorly responsive cell lines, enabling inhibin antagonism of activin signaling.","method":"Crosslinking assays, co-immunoprecipitation, cell-based functional assays, overexpression","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding and functional assays, multiple orthogonal methods, widely replicated","pmids":["10746731"],"is_preprint":false},{"year":1989,"finding":"Betaglycan exists in both membrane-bound and soluble forms. The membrane-bound form is hydrophobic and associates with liposomes; soluble forms lack a membrane anchor. Both forms carry chondroitin sulfate and/or heparan sulfate GAG chains on a 100–120 kDa core protein.","method":"Biochemical characterization, liposome association assay, affinity labeling","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical characterization with multiple orthogonal methods; foundational paper","pmids":["2592419"],"is_preprint":false},{"year":1992,"finding":"Betaglycan binds basic FGF (bFGF) via its heparan sulfate chains (separate domain from TGF-β binding via the core protein). In osteoblasts, bFGF selectively reduces the heparan sulfate GAG content of betaglycan without affecting chondroitin sulfate or core protein size.","method":"Affinity binding assays, metabolic labeling, GAG analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding measurements with domain-specific analysis; replicated concept of dual-domain binding","pmids":["1556106"],"is_preprint":false},{"year":2001,"finding":"Betaglycan ectodomain contains two independent ligand-binding domains: the endoglin-related (membrane-distal) region and the uromodulin-related (membrane-proximal) region. Only the endoglin-related region mediates TGF-β presentation to TβRII. Inhibin A binding resides specifically in the uromodulin-related region. Both regions independently mediate Smad2 phosphorylation.","method":"Deletion mutagenesis, binding assays, Smad2 phosphorylation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis with functional domain mapping, multiple readouts","pmids":["11278442"],"is_preprint":false},{"year":2001,"finding":"In LLC-PK1 renal epithelial cells (which lack endogenous betaglycan), betaglycan expression inhibits TGF-β signaling (Smad2/3 phosphorylation, reporter activity, collagen production) by preventing association between type I and type II TGF-β receptors. This inhibitory function depends on the molecular weight of the GAG chains; a GAG-deficient betaglycan mutant does not inhibit signaling or type I/type II receptor association in these cells.","method":"Reporter assay, thymidine incorporation, collagen production, Smad phosphorylation, co-immunoprecipitation of receptor complexes, GAG mutant analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional assays with mechanistic mutant analysis","pmids":["11668175"],"is_preprint":false},{"year":2003,"finding":"Betaglycan shedding is mediated by MT1-MMP (membrane type-1 matrix metalloprotease), which generates a 90 kDa soluble fragment (sBG-90) in a TIMP-2-sensitive manner. MT3-MMP can also generate this fragment. Pervanadate (a tyrosine phosphatase inhibitor) induces shedding. The shed sBG-90 retains higher affinity for TGF-β2 than TGF-β1.","method":"MT-MMP overexpression, metalloprotease inhibitor treatment, Western blot, binding competition assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — MT1-MMP overexpression in COS-1 cells confirming mechanism, multiple MT-MMP comparisons, two orthogonal methods","pmids":["14672946"],"is_preprint":false},{"year":1994,"finding":"Plasmin selectively cleaves betaglycan on the cell surface, releasing a 60 kDa TGF-β complex into the medium and reducing TGF-β binding to cellular betaglycan. Type I and type II TGF-β receptors are not plasmin substrates. Conditioned medium from plasmin-treated cells contains increased active TGF-β.","method":"Affinity labeling, SDS-PAGE, bioassay for TGF-β activity","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct cell-based cleavage assay with functional readout, single lab","pmids":["8068006"],"is_preprint":false},{"year":2009,"finding":"Soluble betaglycan requires both its N-terminal (45 kDa) and C-terminal (55 kDa) domains tethered together for high-affinity TGF-β binding (low nM Kd). Isolated domains bind TGF-β with 1–2 orders of magnitude lower affinity and have severely diminished ability to neutralize TGF-β activity. Plasmin cleaves the linker between domains, separating them and inactivating TGF-β neutralizing activity.","method":"Plasmin digestion, N-terminal sequencing, surface plasmon resonance, recombinant domain expression, TGF-β neutralization assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with SPR quantification and domain mutagenesis; single lab but multiple orthogonal methods","pmids":["19842711"],"is_preprint":false},{"year":2006,"finding":"Distinct and partially overlapping binding sites for inhibin and TGF-β reside within amino acids 591–700 of betaglycan's ZP domain. Mutation of Val614 to Tyr abolishes both inhibin and TGF-β binding to this domain. Full-length betaglycan V614Y retains TGF-β binding via the N-terminal domain but cannot bind inhibin A or mediate inhibin antagonism of activin signaling, functionally separating these co-receptor actions.","method":"Mutagenesis, binding assays, functional activin/inhibin reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis with functional validation; single lab, multiple orthogonal assays","pmids":["16621788"],"is_preprint":false},{"year":2011,"finding":"Crystal structure (2.0 Å) of betaglycan ZP-C domain reveals an immunoglobulin-like fold. The EHP region is integral to the ZP-C domain. The AB loop and convex surface pocket are implicated in TGF-β ligand binding. Betaglycan lacks the maturation cleavage site present in polymerizing ZP proteins, explaining its non-polymerizing behavior.","method":"X-ray crystallography at 2.0 Å resolution","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — high-resolution crystal structure with structural analysis; single study","pmids":["21402931"],"is_preprint":false},{"year":2016,"finding":"Betaglycan binds TGF-β homodimers with 1:1 stoichiometry and modestly potentiates TβRII binding. Betaglycan must be displaced to allow TβRI to bind. These findings suggest betaglycan concentrates TGF-β2 on the cell surface and promotes TβRII binding via membrane localization and allostery, with TβRI recruitment driving displacement of betaglycan to complete signaling complex formation.","method":"Surface plasmon resonance, isothermal titration calorimetry, size-exclusion chromatography","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — three orthogonal biophysical methods defining stoichiometry and mechanism; single lab","pmids":["27951653"],"is_preprint":false},{"year":2025,"finding":"Cryo-EM/structural analysis of TGF-β bound to betaglycan and signaling receptors (TGFBR1 and TGFBR2) reveals the structural basis for ligand selectivity and provides a structural explanation for the hand-off mechanism in which betaglycan is displaced as signaling receptors engage TGF-β. Binding interfaces differ from those used by the related co-receptor endoglin, demonstrating evolutionary adaptation for ligand selectivity.","method":"Structural determination (cryo-EM/crystallography) of ternary complex","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct structure of betaglycan/TGF-β/signaling receptor complex; single study but high-resolution structural method","pmids":["40011426"],"is_preprint":false},{"year":2018,"finding":"NMR titrations and SPR measurements map the betaglycan ZP-C domain binding site on TGF-β2 to the inner concave surface of its extended finger region, involving residues Ile-92, Lys-97, and Glu-99 that are specific to TGF-β isoforms and InhA α-subunit but absent from other TGF-β family members such as BMP-2.","method":"Methyl-labeled NMR titrations, surface plasmon resonance with TGF-β2 mutant variants","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR and SPR with mutagenesis defining binding interface; single lab, multiple orthogonal methods","pmids":["30598510"],"is_preprint":false},{"year":1998,"finding":"Overexpression of betaglycan in rat myoblasts enhances TGF-β-mediated growth inhibition and PAI-1 expression; betaglycan specifically increases TGF-β binding to the type II receptor. Analysis of endoglin/betaglycan chimeric proteins shows that the extracellular domain governs functional differences between the two co-receptors.","method":"Overexpression in myoblasts, 125I-TGF-β crosslinking, PAI-1 reporter assay, chimeric protein analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional overexpression with ligand binding and reporter assays; chimeric domain analysis; single lab","pmids":["9830054"],"is_preprint":false},{"year":2010,"finding":"Inhibin-A binding to betaglycan causes clathrin-independent endocytic internalization of betaglycan, thereby reducing available TGF-β2 binding sites on the cell surface and antagonizing TGF-β2 signaling. This is distinct from the mechanism by which TGF-β ligands induce betaglycan internalization.","method":"Cell surface binding assays, internalization assays, functional signaling readouts in adrenocortical cells","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic cell-based assays demonstrating internalization and functional consequence; single lab","pmids":["20160125"],"is_preprint":false},{"year":2006,"finding":"Betaglycan overexpression via adenoviral expression induces TGF-β target gene expression (p3TP-Lux, CTGF, fibronectin) and inhibits myogenin expression in the absence of exogenous TGF-β (ligand-independent signaling). This effect requires the cytoplasmic domain of betaglycan and is independent of Smad2 phosphorylation but involves p38 MAP kinase phosphorylation.","method":"Adenoviral overexpression, reporter assays, TGF-β neutralizing antibodies, p38 inhibitor (SB239063), Western blot for phospho-p38 and phospho-Smad2","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple reporter assays with ligand-blocking controls and pharmacological inhibition; single lab","pmids":["16413747"],"is_preprint":false},{"year":2010,"finding":"The transmembrane-cytoplasmic fragment remaining after betaglycan ectodomain shedding is stable in cells and serves as a substrate for γ-secretase intramembrane proteolysis. γ-Secretase inhibition stabilizes the fragment. Expression of this fragment or γ-secretase inhibition blunts TGF-β2 signaling in HepG2 cells.","method":"γ-Secretase inhibitor treatment, ectodomain shedding inhibitor (TAPI-2), Western blot, TGF-β2 signaling reporter","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibitor assays with functional signaling readout; single lab","pmids":["21167215"],"is_preprint":false},{"year":2013,"finding":"Glucocorticoids (dexamethasone and others) upregulate Tgfbr3 expression in lung fibroblasts. Tgfbr3 acts as a 'switch' that blunts Tgfbr1/Smad2/3 signaling and potentiates Acvrl1/Smad1 signaling. Dexamethasone acts synergistically with TGF-β to drive myofibroblast differentiation through Smad1-dependent processes in an in vivo mouse model.","method":"Reporter assays, Western blot for phospho-Smad1 and phospho-Smad2/3, primary cell culture experiments, in vivo mouse dexamethasone treatment, RNAi knockdown","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell types and in vivo validation; single lab","pmids":["24347165"],"is_preprint":false},{"year":2009,"finding":"Tgfbr3 knockout mice exhibit defects in seminiferous cord formation and compromised fetal Leydig cell function (reduced expression of Insl3, Cyp17a1, Cyp11a1, Star, Hsd3b1) without changes in Leydig cell counts, indicating that betaglycan is required for fetal testis structure and Leydig cell endocrine function.","method":"Tgfbr3 knockout mouse analysis, immunohistochemistry, quantitative RT-PCR, whole-mount in situ hybridization, morphometric analysis","journal":"Biology of reproduction","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with multiple cellular and molecular readouts; single lab","pmids":["19696014"],"is_preprint":false},{"year":2011,"finding":"Betaglycan heterozygous mice display augmented nephron number and accelerated ureteric branching, while betaglycan null mice exhibit renal hypoplasia and reduced nephron number. Gene expression analysis links betaglycan dosage to regulation of Bmp4, Pax2, Eya1, Gdnf, Ret, Wnt4, and Wt1 expression in developing kidneys.","method":"Stereological analysis of embryonic/adult kidneys, quantitative RT-PCR, heterozygous and null mouse analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic dosage series with morphometric and molecular endpoints; single lab","pmids":["21533152"],"is_preprint":false},{"year":2009,"finding":"Endogenous betaglycan is required for high-potency inhibin antagonism in rat anterior pituitary gonadotropes. Betaglycan knockdown (siRNA) or immunoneutralization with anti-betaglycan IgG each decreased the potency of inhibin antagonism of activin-induced FSH secretion by more than 1000-fold, without affecting activin responsiveness.","method":"siRNA knockdown, immunoneutralization, primary pituitary gonadotrope culture, FSH secretion assay","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent loss-of-function approaches (siRNA + antibody) with functional FSH secretion readout","pmids":["19372236"],"is_preprint":false},{"year":2018,"finding":"TGFBR3 functions as an obligate inhibin A co-receptor in murine pituitary gonadotropes in vivo, but is not required for inhibin B suppression of FSH. Conditional knockout of Tgfbr3 in gonadotropes impairs inhibin A but not inhibin B suppression of FSH synthesis in cultured pituitaries.","method":"Conditional gonadotrope-specific Tgfbr3 knockout mice, pituitary cell culture, FSH assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific functional readout; single lab, in vivo genetic model","pmids":["30364975"],"is_preprint":false},{"year":2016,"finding":"TGFBR3 regulates canonical Wnt3a signaling independently of its TGF-β co-receptor function. Heparan sulfate GAG chains on TGFBR3 sequester Wnt3a and inhibit Wnt signaling, while chondroitin sulfate GAG chains promote Wnt3a signaling. The balance of these modifications determines the net effect on Wnt pathway activation.","method":"Overexpression/knockdown, luciferase reporter assays for Wnt signaling, GAG-deficient and sulfation mutants","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple constructs with different GAG modifications, reporter assays; single lab","pmids":["27784788"],"is_preprint":false},{"year":2008,"finding":"The inhibin A binding epitope on betaglycan involves residues Tyr50, Val108, Thr111, Ser112, Phe118, Lys119, and Tyr120 of the inhibin α-subunit. Simultaneous mutation of Thr111, Ser112, and Tyr120 to alanine abolishes betaglycan binding and renders inhibin A unable to suppress activin-induced FSH release from pituitary cells.","method":"Mutagenesis of inhibin A, binding assays, pituitary cell FSH bioassay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of ligand binding interface with functional FSH suppression readout; single lab, multiple orthogonal methods","pmids":["18397882"],"is_preprint":false},{"year":2019,"finding":"Loss of TGFBR3 in clear-cell renal cell carcinoma enhances cell migration through TGF-β-independent activation of FAK-PI3K signaling with increased lamellipodium formation, and also enhances TGF-β2-dependent reduction in the ALDH-positive cancer-initiating cell population. Orthotopic inoculation showed that low TGFBR3 enhances primary tumor formation and lung metastasis.","method":"Orthotopic mouse inoculation, cell migration assays, ALDH flow cytometry, signaling pathway inhibitors","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo orthotopic model with mechanistic pathway analysis; single lab","pmids":["29391598"],"is_preprint":false},{"year":2019,"finding":"Betaglycan loss in MSCs augments TGF-β signaling, blocks the MSC-osteoblast differentiation program, and is required for prostate cancer-induced osteogenesis in vivo. Mechanistically, betaglycan loss induces >60-fold increase in Wnt5a expression, activating canonical Wnt signaling; Wnt5a neutralizing antibody rescues osteogenic gene expression in betaglycan-ablated MSCs.","method":"Betaglycan knockdown in MSCs, osteoblast differentiation assays, in vivo xenograft osteogenesis, gene expression analysis, Wnt5a neutralizing antibody rescue","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo model with mechanistic rescue experiment; single lab","pmids":["31409900"],"is_preprint":false},{"year":2014,"finding":"TGFBR3 forms a complex with β-arrestin 2 and IκBα. Overexpression of TGFBR3 decreases phospho-p65 (NF-κB) and increases IκBα expression in oral cancer cells; these effects are abolished by β-arrestin 2 knockdown.","method":"Co-immunoprecipitation, Western blot, siRNA knockdown","journal":"Cell adhesion & migration","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP with functional knockdown rescue; single lab","pmids":["29130787"],"is_preprint":false},{"year":2014,"finding":"Betaglycan suppresses NFκB activity in granulosa tumor cells, reduces basal and TGF-β2-stimulated NFκB activity, and reduces cell viability in concert with NFκB inhibition. ERK1/2 activation converges the NFκB, SMAD3, and TGF-β2/betaglycan pathways. SMAD3 and NFκB form a positive feedback loop; betaglycan expression disrupts this loop.","method":"NFκB reporter assay, SMAD2/3 knockdown, pharmacological NFκB inhibition, cell viability assay, overexpression of betaglycan in GCT cell lines","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway intervention assays with functional readout; confirmed in two cell lines","pmids":["23322721"],"is_preprint":false},{"year":2012,"finding":"Granzyme B cleaves soluble betaglycan as an extracellular substrate, releasing active TGF-β1 sequestered by betaglycan. Released TGF-β1 retains bioactivity as demonstrated by Smad3 phosphorylation in smooth muscle cells.","method":"In vitro protease cleavage assay, TGF-β1 cytokine release assay, Smad3 phosphorylation Western blot","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro cleavage with functional TGF-β1 activity readout; single lab","pmids":["22479366"],"is_preprint":false},{"year":2014,"finding":"Lactoferrin directly binds betaglycan (TGFBR3) and induces formation of TβRIII/TβRII/TβRI complex, leading to TβRI and Smad3 phosphorylation and IgA/IgG2b isotype switching in B cells. This represents a ligand-mediated mechanism for betaglycan to initiate canonical TGF-β signaling.","method":"Binding assays (lactoferrin-betaglycan direct interaction), co-immunoprecipitation of receptor complex, Western blot for Smad3 phosphorylation, B cell Ig class switching assays","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding plus complex formation plus functional signaling readout; single lab","pmids":["25492477"],"is_preprint":false},{"year":2002,"finding":"TGF-β competes with inhibin A for binding to betaglycan on gonadotrope cells, reducing inhibin's ability to antagonize activin-induced FSH synthesis. TGF-β1 and TGF-β2 competed with 125I-inhibin for betaglycan binding in crosslinking experiments, suggesting TGF-β can counter inhibin action by occupying the shared betaglycan binding site.","method":"Radiolabeled inhibin A competition binding, immunoprecipitation of crosslinked receptor complexes, activin-responsive reporter assays in LβT2 cells","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal competition binding with functional reporter assay; single lab","pmids":["12456797"],"is_preprint":false},{"year":2000,"finding":"Endoglin associates with betaglycan on human microvascular endothelial cells in a ligand-dependent and ligand-independent manner to form higher-order complexes that also include type I and/or type II TGF-β receptors.","method":"Co-immunoprecipitation, affinity labeling with radiolabeled TGF-β","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP and affinity labeling in endogenous cell context; single lab","pmids":["10951214"],"is_preprint":false},{"year":2003,"finding":"Endoglin forms a heteromeric complex with betaglycan on human chondrocytes in both a ligand-independent and ligand-dependent manner, independently of the type II TGF-β receptor.","method":"Co-immunoprecipitation in absence of TGF-β and after affinity labeling with radiolabeled TGF-β","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP with two conditions (ligand-dependent and independent); single lab","pmids":["12568406"],"is_preprint":false},{"year":2007,"finding":"TGF-β1 pretreatment of Leydig (TM3) and Sertoli (TM4) cells suppresses betaglycan mRNA levels by 46–73%, reducing subsequent inhibin A binding and betaglycan affinity labeling. This represents an indirect mechanism by which TGF-β blocks inhibin binding via downregulation of betaglycan. In cells lacking TβRII, only direct ligand competition is operational.","method":"RT-PCR, 125I-inhibin A affinity labeling, betaglycan mRNA quantification","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell lines, quantified binding and expression changes; single lab","pmids":["17656464"],"is_preprint":false},{"year":2019,"finding":"TGFBR3 is identified as a target of let-7 microRNAs; induction of Tgfbr3 in cardiomyocytes causes apoptosis via p38 MAPK activation following myocardial infarction. AAV9-mediated let-7 overexpression reduced cardiomyocyte apoptosis, cardiac hypertrophy, and improved ejection fraction.","method":"AAV9-mediated microRNA overexpression/knockdown in mice, MI model, apoptosis assays, Western blot for p38 MAPK activation","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo AAV-mediated gain/loss-of-function with functional cardiac readouts; single lab","pmids":["31401194"],"is_preprint":false},{"year":2024,"finding":"Cancer-associated fibroblast-secreted SULF1 binds TGFBR3 on gastric cancer cell membranes, interfering with TGF-β1/TGFBR3 interaction and subsequently activating downstream TGF-β signaling to promote metastasis and CDDP resistance.","method":"Co-immunoprecipitation/binding assays, functional migration and drug resistance assays, in vitro cancer-fibroblast co-culture system","journal":"Cell death discovery","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, binding and functional assays but mechanistic detail limited in abstract","pmids":["38438372"],"is_preprint":false}],"current_model":"TGFBR3 (betaglycan) is a membrane-anchored heparan sulfate/chondroitin sulfate proteoglycan that functions as a multi-ligand co-receptor: it presents TGF-β (especially TGF-β2) to the type II signaling receptor by forming a high-affinity ternary complex (requiring membrane anchorage and its N-terminal endoglin-related domain), acts as a high-affinity inhibin A co-receptor via its C-terminal ZP domain to potentiate inhibin antagonism of activin signaling, and can modulate Wnt and NF-κB pathways independently of TGF-β; its ectodomain is shed by MT1-MMP and further processed by γ-secretase, converting it from a TGF-β enhancer to an antagonist; depending on cell context and GAG chain composition, betaglycan can either enhance or inhibit TGF-β signaling by controlling type I/type II receptor complex formation."},"narrative":{"mechanistic_narrative":"TGFBR3 (betaglycan) is a membrane-anchored heparan sulfate/chondroitin sulfate proteoglycan that functions as a multi-ligand co-receptor controlling the access of TGF-β superfamily ligands to their signaling receptors [PMID:8391934, PMID:1657406]. It captures TGF-β—including isoforms that bind the signaling receptors poorly—through its N-terminal endoglin-related domain and presents it to the type II receptor (TβRII), forming a high-affinity ternary complex that requires membrane anchorage and equalizes the activity of TGF-β isoforms [PMID:8391934, PMID:8106553, PMID:11278442]; subsequent recruitment of TβRI drives displacement of betaglycan to complete the signaling complex, a hand-off mechanism resolved structurally [PMID:27951653, PMID:40011426]. High-affinity ligand binding depends on cooperation between its N-terminal endoglin-related and C-terminal zona pellucida (ZP) domains tethered together [PMID:19842711, PMID:21402931]. Through the ZP domain it acts as an obligate high-affinity inhibin A co-receptor with ActRII, conferring inhibin sensitivity and enabling inhibin antagonism of activin signaling—a function genetically separable from TGF-β presentation and required in vivo for inhibin A suppression of pituitary FSH [PMID:10746731, PMID:16621788, PMID:19372236, PMID:30364975]. Betaglycan's net effect on TGF-β signaling is context-dependent: depending on cell type and GAG composition it either enhances signaling or inhibits it by blocking type I/type II receptor association, the latter requiring intact GAG chains [PMID:11668175, PMID:9830054]. Its ectodomain is shed by MT1-MMP/MT3-MMP to yield a soluble TGF-β-neutralizing antagonist, and the residual membrane stub is cleaved by γ-secretase, converting betaglycan from a signaling enhancer into an antagonist [PMID:14672946, PMID:21167215]. Independently of TGF-β, betaglycan modulates canonical Wnt signaling via its GAG chains and suppresses NF-κB activity through a β-arrestin 2/IκBα complex [PMID:27784788, PMID:29130787, PMID:23322721]. Loss-of-function in mice establishes betaglycan as required for fetal testis cord formation and Leydig cell endocrine function and for proper kidney nephron number and ureteric branching [PMID:19696014, PMID:21533152].","teleology":[{"year":1989,"claim":"Established that betaglycan exists as both membrane-bound and soluble GAG-bearing proteoglycan forms, defining the structural basis for its dual cell-surface and soluble functions.","evidence":"Biochemical characterization, liposome association and affinity labeling","pmids":["2592419"],"confidence":"High","gaps":["Did not define the ligand-presentation function","GAG contribution to function not yet tested"]},{"year":1991,"claim":"cDNA cloning revealed the domain architecture—extracellular GAG-bearing ectodomain with transmembrane/cytoplasmic homology to endoglin—and showed GAG chains are dispensable for TGF-β binding to the core protein, separating ligand binding from glycosylation.","evidence":"cDNA cloning, sequencing and domain analysis","pmids":["1657406"],"confidence":"High","gaps":["Functional role of cytoplasmic domain unresolved","Mechanism of presentation to signaling receptors not addressed"]},{"year":1993,"claim":"Demonstrated the core co-receptor mechanism: betaglycan presents TGF-β to the type II receptor in a high-affinity ternary complex and eliminates isoform-specific differences in signaling potency.","evidence":"Receptor binding/crosslinking and cell-based functional assays with overexpression","pmids":["8391934"],"confidence":"High","gaps":["Structural basis of the ternary complex not defined","How TβRI is recruited unknown"]},{"year":1994,"claim":"Mapped TGF-β binding to the N-terminal endoglin-related region, localized GAG attachment sites (Ser535/Ser546), and showed membrane anchorage is required for presentation while soluble betaglycan acts as a TGF-β antagonist—defining the enhancer-versus-antagonist duality.","evidence":"Site-directed and deletion mutagenesis with binding assays; plasmin cleavage assays","pmids":["8106553","8068006"],"confidence":"High","gaps":["Second ligand-binding domain not yet defined","Physiological proteases controlling shedding unknown"]},{"year":1992,"claim":"Showed dual-domain binding capacity—bFGF binds heparan sulfate chains independently of TGF-β binding to the core—establishing betaglycan as a multi-ligand proteoglycan.","evidence":"Affinity binding, metabolic labeling and GAG analysis in osteoblasts","pmids":["1556106"],"confidence":"High","gaps":["Signaling consequence of bFGF binding not established"]},{"year":2000,"claim":"Identified betaglycan as a high-affinity inhibin co-receptor that partners with ActRII to confer inhibin sensitivity, extending its role beyond TGF-β to activin antagonism.","evidence":"Crosslinking, co-IP and functional cell assays with overexpression","pmids":["10746731"],"confidence":"High","gaps":["Inhibin-binding domain not localized","In vivo physiological requirement untested"]},{"year":2001,"claim":"Resolved a two-domain ligand architecture (endoglin-related for TGF-β presentation, uromodulin/ZP-related for inhibin A) and showed that in cells lacking endogenous betaglycan its expression inhibits TGF-β signaling by preventing type I/type II receptor association in a GAG-dependent manner.","evidence":"Deletion mutagenesis, Smad2 phosphorylation, receptor co-IP and GAG mutant analysis","pmids":["11278442","11668175"],"confidence":"High","gaps":["Why context determines enhancement vs inhibition not fully resolved","Role of GAG chain size mechanistically incomplete"]},{"year":2003,"claim":"Identified MT1-MMP/MT3-MMP as the proteases that shed the betaglycan ectodomain, defining the regulated step that generates the soluble TGF-β antagonist.","evidence":"MT-MMP overexpression, metalloprotease inhibition and binding assays","pmids":["14672946"],"confidence":"High","gaps":["Physiological triggers of shedding in vivo unclear","Fate of the membrane stub not addressed here"]},{"year":2006,"claim":"Functionally separated betaglycan's co-receptor roles by mapping overlapping inhibin/TGF-β sites in the ZP domain (V614Y abolishes both) and identifying ligand-independent signaling requiring the cytoplasmic domain via p38 MAPK.","evidence":"Mutagenesis with functional reporters; adenoviral overexpression with p38 inhibitor","pmids":["16621788","16413747"],"confidence":"Medium","gaps":["Cytoplasmic-domain signaling partners undefined","Relationship between p38 axis and canonical Smad signaling unclear"]},{"year":2008,"claim":"Defined the inhibin α-subunit residues forming the betaglycan-binding epitope, linking a precise molecular interface to FSH regulation.","evidence":"Inhibin A mutagenesis, binding assays and pituitary FSH bioassay","pmids":["18397882"],"confidence":"High","gaps":["Reciprocal betaglycan residues not all defined here"]},{"year":2009,"claim":"Showed that high-affinity soluble betaglycan requires both N- and C-terminal domains tethered together and that endogenous betaglycan is functionally required for high-potency inhibin antagonism in gonadotropes.","evidence":"SPR with recombinant domains and plasmin digestion; siRNA and immunoneutralization in pituitary cells; Tgfbr3-null mouse testis analysis","pmids":["19842711","19372236","19696014"],"confidence":"High","gaps":["Structural picture of two-domain ligand engagement still indirect","Tissue-specific downstream effectors incompletely mapped"]},{"year":2010,"claim":"Identified the post-shedding steps—γ-secretase processing of the membrane stub and inhibin-A-induced clathrin-independent internalization—that convert betaglycan into a TGF-β antagonist and reduce surface ligand sites.","evidence":"γ-secretase/shedding inhibitors with signaling reporters; cell-surface internalization assays","pmids":["21167215","20160125"],"confidence":"Medium","gaps":["Downstream fate/function of the intracellular fragment unknown","Internalization machinery not molecularly defined"]},{"year":2011,"claim":"Provided the high-resolution crystal structure of the ZP-C domain (Ig-like fold, integral EHP region) and genetic dosage analysis linking betaglycan levels to kidney nephron number and branching gene programs.","evidence":"X-ray crystallography at 2.0 Å; stereological and qRT-PCR analysis of heterozygous/null mouse kidneys","pmids":["21402931","21533152"],"confidence":"High","gaps":["Structure of the full ligand-bound complex not yet available","Mechanism connecting dosage to branching genes correlative"]},{"year":2016,"claim":"Defined the biophysical hand-off model—betaglycan binds TGF-β 1:1, modestly potentiates TβRII binding, and must be displaced for TβRI to engage—and uncovered a GAG-dependent, TGF-β-independent role in Wnt3a signaling.","evidence":"SPR/ITC/SEC stoichiometry; Wnt luciferase reporters with GAG/sulfation mutants","pmids":["27951653","27784788"],"confidence":"High","gaps":["Structural geometry of displacement not directly observed at this stage","Wnt-modulating GAG mechanism not resolved in vivo"]},{"year":2018,"claim":"Defined the TGF-β2 surface engaged by the betaglycan ZP-C domain and established betaglycan as an obligate inhibin A (but not inhibin B) co-receptor in gonadotropes in vivo.","evidence":"NMR/SPR interface mapping with TGF-β2 mutants; conditional gonadotrope Tgfbr3 knockout with FSH assay","pmids":["30598510","30364975"],"confidence":"High","gaps":["Molecular basis of inhibin A vs inhibin B discrimination unresolved"]},{"year":2019,"claim":"Established context-specific tumor and tissue roles: betaglycan loss promotes renal carcinoma migration/metastasis via FAK-PI3K and prostate-cancer-induced osteogenesis via Wnt5a, and let-7-driven TGFBR3 induction promotes cardiomyocyte apoptosis after infarction.","evidence":"Orthotopic/xenograft mouse models, pathway inhibitors, Wnt5a-neutralization rescue, AAV9 microRNA modulation","pmids":["29391598","31409900","31401194"],"confidence":"Medium","gaps":["Direct molecular link between betaglycan and FAK-PI3K not defined","Disease relevance to human pathology correlative"]},{"year":2025,"claim":"Provided the structural basis for the betaglycan-to-signaling-receptor hand-off and for ligand selectivity, showing interfaces distinct from endoglin.","evidence":"Cryo-EM/structural determination of TGF-β/betaglycan/TGFBR1/TGFBR2 complex","pmids":["40011426"],"confidence":"High","gaps":["Dynamics and kinetics of displacement in living membranes not captured","GAG-chain contribution to the complex not structurally resolved"]},{"year":null,"claim":"How GAG chain composition, ectodomain shedding, and cell context are integrated to switch betaglycan between TGF-β enhancer and antagonist in specific tissues remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking GAG editing to context-dependent signaling output","In vivo regulators of the enhancer/antagonist switch not identified","Mendelian disease association not established in this corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,6,13,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,3,7,23]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,32]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,13]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2,4,7]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,8,10,31]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,7,13]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[21,22]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[23,24]}],"complexes":["TGF-β/betaglycan/TβRII/TβRI ternary signaling complex","inhibin A/betaglycan/ActRII co-receptor complex","betaglycan/β-arrestin 2/IκBα complex"],"partners":["TGFBR2","TGFBR1","ACVR2A","ENG","ARRB2","NFKBIA","MMP14"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q03167","full_name":"Transforming growth factor beta receptor type 3","aliases":["Betaglycan","Transforming growth factor beta receptor III","TGF-beta receptor type III"],"length_aa":851,"mass_kda":93.5,"function":"Cell surface receptor that regulates diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis (PubMed:12958365, PubMed:19416857). Initiates BMP, inhibin, and TGF-beta signaling pathways by interacting with different ligands including TGFB1, BMP2, BMP5, BMP7 or GDF5 (PubMed:18184661). Alternatively, acts as a cell surface coreceptor for BMP ligands, serving to enhance ligand binding by differentially regulating BMPR1A/ALK3 and BMPR1B/ALK6 receptor trafficking (PubMed:19726563). Promotes epithelial cell adhesion, focal adhesion formation and integrin signaling during epithelial cell spreading on fibronectin (PubMed:22562249). By interacting with the scaffolding protein beta-arrestin2/ARRB2, regulates migration or actin cytoskeleton and promotes the activation of CDC42 as well as the inhibition of NF-kappa-B (PubMed:19416857, PubMed:19325136). In gonadotrope cells, acts as an inhibin A coreceptor and regulates follicle-stimulating hormone (FSH) levels and female fertility (By similarity). Plays a role in the inhibition of directed and random cell migration in epithelial cells by altering the actin cytoskeletal organization (PubMed:19416857). Participates in epithelial-mesenchymal transformation (EMT) upon binding to BMP2 or TGFB2, by activating the PAR6/SMURF1/RHOA pathway (By similarity) (Microbial infection) May act as a receptor for human cytomegalovirus in different cell types by interacting with HCMV trimer composed of GO, GH and GL","subcellular_location":"Cell membrane; Secreted; Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q03167/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TGFBR3","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TGFBR3","total_profiled":1310},"omim":[{"mim_id":"612728","title":"BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 14; BMND14","url":"https://www.omim.org/entry/612728"},{"mim_id":"612727","title":"BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 13; BMND13","url":"https://www.omim.org/entry/612727"},{"mim_id":"604383","title":"GROWTH FACTOR-INDEPENDENT 1B; GFI1B","url":"https://www.omim.org/entry/604383"},{"mim_id":"600742","title":"TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE III; TGFBR3","url":"https://www.omim.org/entry/600742"},{"mim_id":"190181","title":"TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE I; TGFBR1","url":"https://www.omim.org/entry/190181"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TGFBR3"},"hgnc":{"alias_symbol":["betaglycan","BGCAN"],"prev_symbol":[]},"alphafold":{"accession":"Q03167","domains":[{"cath_id":"-","chopping":"46-216","consensus_level":"high","plddt":87.9991,"start":46,"end":216},{"cath_id":"-","chopping":"217-356","consensus_level":"high","plddt":84.1866,"start":217,"end":356},{"cath_id":"2.60.40.3210","chopping":"453-529_566-574","consensus_level":"high","plddt":77.0233,"start":453,"end":574},{"cath_id":"2.60.40.4100","chopping":"592-756","consensus_level":"high","plddt":79.9924,"start":592,"end":756}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03167","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q03167-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q03167-F1-predicted_aligned_error_v6.png","plddt_mean":71.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TGFBR3","jax_strain_url":"https://www.jax.org/strain/search?query=TGFBR3"},"sequence":{"accession":"Q03167","fasta_url":"https://rest.uniprot.org/uniprotkb/Q03167.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q03167/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03167"}},"corpus_meta":[{"pmid":"8391934","id":"PMC_8391934","title":"Betaglycan presents ligand to the TGF beta signaling receptor.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8391934","citation_count":816,"is_preprint":false},{"pmid":"1657406","id":"PMC_1657406","title":"Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system.","date":"1991","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1657406","citation_count":613,"is_preprint":false},{"pmid":"10746731","id":"PMC_10746731","title":"Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10746731","citation_count":479,"is_preprint":false},{"pmid":"8106553","id":"PMC_8106553","title":"Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8106553","citation_count":350,"is_preprint":false},{"pmid":"2592419","id":"PMC_2592419","title":"Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta.","date":"1989","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/2592419","citation_count":334,"is_preprint":false},{"pmid":"31307515","id":"PMC_31307515","title":"Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31307515","citation_count":281,"is_preprint":false},{"pmid":"9830054","id":"PMC_9830054","title":"Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9830054","citation_count":193,"is_preprint":false},{"pmid":"11278442","id":"PMC_11278442","title":"Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278442","citation_count":135,"is_preprint":false},{"pmid":"1556106","id":"PMC_1556106","title":"Binding of two growth factor families to separate domains of the proteoglycan betaglycan.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1556106","citation_count":127,"is_preprint":false},{"pmid":"12183427","id":"PMC_12183427","title":"Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12183427","citation_count":124,"is_preprint":false},{"pmid":"11668175","id":"PMC_11668175","title":"Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11668175","citation_count":116,"is_preprint":false},{"pmid":"14672946","id":"PMC_14672946","title":"The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14672946","citation_count":105,"is_preprint":false},{"pmid":"21717526","id":"PMC_21717526","title":"Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor.","date":"2011","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21717526","citation_count":100,"is_preprint":false},{"pmid":"17522389","id":"PMC_17522389","title":"Loss of betaglycan expression in ovarian cancer: role in motility and invasion.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17522389","citation_count":99,"is_preprint":false},{"pmid":"22479366","id":"PMC_22479366","title":"Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-β1.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22479366","citation_count":96,"is_preprint":false},{"pmid":"21550381","id":"PMC_21550381","title":"Betaglycan: a multifunctional accessory.","date":"2011","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21550381","citation_count":94,"is_preprint":false},{"pmid":"11912285","id":"PMC_11912285","title":"Expression of activin receptors, follistatin and betaglycan by human endometrial stromal cells; consistent with a role for activins during decidualization.","date":"2002","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/11912285","citation_count":84,"is_preprint":false},{"pmid":"11256966","id":"PMC_11256966","title":"Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent.","date":"2001","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11256966","citation_count":78,"is_preprint":false},{"pmid":"29707897","id":"PMC_29707897","title":"Upregulated lncRNA ADAMTS9-AS2 suppresses progression of lung cancer through inhibition of miR-223-3p and promotion of TGFBR3.","date":"2018","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/29707897","citation_count":78,"is_preprint":false},{"pmid":"21792916","id":"PMC_21792916","title":"TGFBR3, a potential negative regulator of TGF-β signaling, protects cardiac fibroblasts from hypoxia-induced apoptosis.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21792916","citation_count":71,"is_preprint":false},{"pmid":"12385827","id":"PMC_12385827","title":"Properties of inhibin binding to betaglycan, InhBP/p120 and the activin type II receptors.","date":"2002","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12385827","citation_count":70,"is_preprint":false},{"pmid":"16621788","id":"PMC_16621788","title":"Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16621788","citation_count":69,"is_preprint":false},{"pmid":"10951214","id":"PMC_10951214","title":"Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors.","date":"2000","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10951214","citation_count":68,"is_preprint":false},{"pmid":"24658685","id":"PMC_24658685","title":"A time- and matrix-dependent TGFBR3-JUND-KRT5 regulatory circuit in single breast epithelial cells and basal-like premalignancies.","date":"2014","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24658685","citation_count":66,"is_preprint":false},{"pmid":"24705316","id":"PMC_24705316","title":"TGFBR3 and MGEA5 rearrangements in pleomorphic hyalinizing angiectatic tumors and the spectrum of related neoplasms.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24705316","citation_count":61,"is_preprint":false},{"pmid":"29391598","id":"PMC_29391598","title":"Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29391598","citation_count":60,"is_preprint":false},{"pmid":"15468171","id":"PMC_15468171","title":"Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.","date":"2005","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/15468171","citation_count":60,"is_preprint":false},{"pmid":"8226781","id":"PMC_8226781","title":"Localization of transforming growth factor beta binding site in betaglycan. Comparison with small extracellular matrix proteoglycans.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8226781","citation_count":60,"is_preprint":false},{"pmid":"33307448","id":"PMC_33307448","title":"Regulation of H2S-induced necroptosis and inflammation in broiler bursa of Fabricius by the miR-15b-5p/TGFBR3 axis and the involvement of oxidative stress in this process.","date":"2020","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/33307448","citation_count":58,"is_preprint":false},{"pmid":"24347165","id":"PMC_24347165","title":"Glucocorticoids recruit Tgfbr3 and Smad1 to shift transforming growth factor-β signaling from the Tgfbr1/Smad2/3 axis to the Acvrl1/Smad1 axis in lung fibroblasts.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24347165","citation_count":58,"is_preprint":false},{"pmid":"11861534","id":"PMC_11861534","title":"The distribution of betaglycan protein and mRNA in rat brain, pituitary, and gonads: implications for a role for betaglycan in inhibin-mediated reproductive functions.","date":"2002","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11861534","citation_count":58,"is_preprint":false},{"pmid":"12052232","id":"PMC_12052232","title":"Expression and localization of inhibin alpha, inhibin/activin betaA and betaB and the activin type II and inhibin beta-glycan receptors in the developing human testis.","date":"2002","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12052232","citation_count":57,"is_preprint":false},{"pmid":"17192875","id":"PMC_17192875","title":"TGFBR3 loss and consequences in prostate cancer.","date":"2007","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/17192875","citation_count":56,"is_preprint":false},{"pmid":"19696014","id":"PMC_19696014","title":"Fetal testis dysgenesis and compromised Leydig cell function in Tgfbr3 (beta glycan) knockout mice.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19696014","citation_count":56,"is_preprint":false},{"pmid":"1744125","id":"PMC_1744125","title":"Purification of the transforming growth factor-beta (TGF-beta) binding proteoglycan betaglycan.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1744125","citation_count":56,"is_preprint":false},{"pmid":"20739376","id":"PMC_20739376","title":"Changes in expression of bone morphogenetic proteins (BMPs), their receptors and inhibin co-receptor betaglycan during bovine antral follicle development: inhibin can antagonize the suppressive effect of BMPs on thecal androgen production.","date":"2010","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20739376","citation_count":55,"is_preprint":false},{"pmid":"31601110","id":"PMC_31601110","title":"Structural biology of betaglycan and endoglin, membrane-bound co-receptors of the TGF-beta family.","date":"2019","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/31601110","citation_count":54,"is_preprint":false},{"pmid":"35369660","id":"PMC_35369660","title":"Transforming Growth Factor Beta Receptor 3 (TGFBR3)-Associated Membranous Nephropathy.","date":"2021","source":"Kidney360","url":"https://pubmed.ncbi.nlm.nih.gov/35369660","citation_count":49,"is_preprint":false},{"pmid":"1310325","id":"PMC_1310325","title":"Subtypes of betaglycan and of type I and type II transforming growth factor-beta (TGF-beta) receptors with different affinities for TGF-beta 1 and TGF-beta 2 are exhibited by human placental trophoblast cells.","date":"1992","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/1310325","citation_count":49,"is_preprint":false},{"pmid":"16954341","id":"PMC_16954341","title":"Soluble betaglycan reduces renal damage progression in db/db mice.","date":"2006","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16954341","citation_count":48,"is_preprint":false},{"pmid":"19164448","id":"PMC_19164448","title":"Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19164448","citation_count":47,"is_preprint":false},{"pmid":"30729664","id":"PMC_30729664","title":"Novel role of the clustered miR-23b-3p and miR-27b-3p in enhanced expression of fibrosis-associated genes by targeting TGFBR3 in atrial fibroblasts.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30729664","citation_count":45,"is_preprint":false},{"pmid":"21402931","id":"PMC_21402931","title":"Structure of betaglycan zona pellucida (ZP)-C domain provides insights into ZP-mediated protein polymerization and TGF-beta binding.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21402931","citation_count":45,"is_preprint":false},{"pmid":"30364975","id":"PMC_30364975","title":"Betaglycan (TGFBR3) Functions as an Inhibin A, but Not Inhibin B, Coreceptor in Pituitary Gonadotrope Cells in Mice.","date":"2018","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30364975","citation_count":44,"is_preprint":false},{"pmid":"11818494","id":"PMC_11818494","title":"Inhibin binding protein (InhBP/p120), betaglycan, and the continuing search for the inhibin receptor.","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11818494","citation_count":43,"is_preprint":false},{"pmid":"14500575","id":"PMC_14500575","title":"Betaglycan localization in the female rat pituitary: implications for the regulation of follicle-stimulating hormone by inhibin.","date":"2003","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/14500575","citation_count":43,"is_preprint":false},{"pmid":"11911962","id":"PMC_11911962","title":"Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan.","date":"2002","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11911962","citation_count":42,"is_preprint":false},{"pmid":"12399463","id":"PMC_12399463","title":"Betaglycan expression is transcriptionally up-regulated during skeletal muscle differentiation. Cloning of murine betaglycan gene promoter and its modulation by MyoD, retinoic acid, and transforming growth factor-beta.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12399463","citation_count":40,"is_preprint":false},{"pmid":"27951653","id":"PMC_27951653","title":"Binding Properties of the Transforming Growth Factor-β Coreceptor Betaglycan: Proposed Mechanism for Potentiation of Receptor Complex Assembly and Signaling.","date":"2016","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27951653","citation_count":40,"is_preprint":false},{"pmid":"32491253","id":"PMC_32491253","title":"The STAT3-miR-223-TGFBR3/HMGCS1 axis modulates the progression of cervical carcinoma.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32491253","citation_count":39,"is_preprint":false},{"pmid":"8068006","id":"PMC_8068006","title":"Plasmin cleaves betaglycan and releases a 60 kDa transforming growth factor-beta complex from the cell surface.","date":"1994","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8068006","citation_count":39,"is_preprint":false},{"pmid":"18397882","id":"PMC_18397882","title":"Suppression of inhibin A biological activity by alterations in the binding site for betaglycan.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18397882","citation_count":39,"is_preprint":false},{"pmid":"16413747","id":"PMC_16413747","title":"Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16413747","citation_count":39,"is_preprint":false},{"pmid":"19842711","id":"PMC_19842711","title":"Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19842711","citation_count":39,"is_preprint":false},{"pmid":"29130787","id":"PMC_29130787","title":"miR-19a and miR-424 target TGFBR3 to promote epithelial-to-mesenchymal transition and migration of tongue squamous cell carcinoma cells.","date":"2017","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/29130787","citation_count":38,"is_preprint":false},{"pmid":"31401194","id":"PMC_31401194","title":"MicroRNA let-7-TGFBR3 signalling regulates cardiomyocyte apoptosis after infarction.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31401194","citation_count":38,"is_preprint":false},{"pmid":"19372236","id":"PMC_19372236","title":"Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19372236","citation_count":38,"is_preprint":false},{"pmid":"15745937","id":"PMC_15745937","title":"Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma.","date":"2005","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15745937","citation_count":38,"is_preprint":false},{"pmid":"12568406","id":"PMC_12568406","title":"Endoglin is expressed on human chondrocytes and forms a heteromeric complex with betaglycan in a ligand and type II TGFbeta receptor independent manner.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/12568406","citation_count":38,"is_preprint":false},{"pmid":"18236212","id":"PMC_18236212","title":"Differential expression of TGFBR3 (betaglycan) in mouse ovary and testis during gonadogenesis.","date":"2007","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/18236212","citation_count":37,"is_preprint":false},{"pmid":"37794449","id":"PMC_37794449","title":"Exosome-derived circ_0001785 delays atherogenesis through the ceRNA network mechanism of miR-513a-5p/TGFBR3.","date":"2023","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37794449","citation_count":36,"is_preprint":false},{"pmid":"20160125","id":"PMC_20160125","title":"Inhibin-A antagonizes TGFbeta2 signaling by down-regulating cell surface expression of the TGFbeta coreceptor betaglycan.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20160125","citation_count":36,"is_preprint":false},{"pmid":"8645162","id":"PMC_8645162","title":"Betaglycan has multiple binding sites for transforming growth factor-beta 1.","date":"1996","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8645162","citation_count":36,"is_preprint":false},{"pmid":"25492477","id":"PMC_25492477","title":"Lactoferrin causes IgA and IgG2b isotype switching through betaglycan binding and activation of canonical TGF-β signaling.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25492477","citation_count":35,"is_preprint":false},{"pmid":"31525642","id":"PMC_31525642","title":"Hsa_circ_0042666 inhibits proliferation and invasion via regulating miR-223/TGFBR3 axis in laryngeal squamous cell carcinoma.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31525642","citation_count":33,"is_preprint":false},{"pmid":"12456797","id":"PMC_12456797","title":"Transforming growth factor-beta modulates inhibin A bioactivity in the LbetaT2 gonadotrope cell line by competing for binding to betaglycan.","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12456797","citation_count":32,"is_preprint":false},{"pmid":"30467960","id":"PMC_30467960","title":"MicroRNA let-7a regulates angiogenesis by targeting TGFBR3 mRNA.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30467960","citation_count":31,"is_preprint":false},{"pmid":"36897738","id":"PMC_36897738","title":"Exosomal miR-103a-3p from Crohn's Creeping Fat-Derived Adipose-Derived Stem Cells Contributes to Intestinal Fibrosis by Targeting TGFBR3 and Activating Fibroblasts.","date":"2023","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/36897738","citation_count":31,"is_preprint":false},{"pmid":"34129838","id":"PMC_34129838","title":"Inhibiting microRNA-424 in bone marrow mesenchymal stem cells-derived exosomes suppresses tumor growth in colorectal cancer by upregulating TGFBR3.","date":"2021","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/34129838","citation_count":30,"is_preprint":false},{"pmid":"17845732","id":"PMC_17845732","title":"Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells.","date":"2007","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17845732","citation_count":30,"is_preprint":false},{"pmid":"11451571","id":"PMC_11451571","title":"Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan-glycan.","date":"2001","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11451571","citation_count":29,"is_preprint":false},{"pmid":"7559813","id":"PMC_7559813","title":"Serglycin and betaglycan proteoglycans are expressed in the megakaryocytic cell line CHRF 288-11 and normal human megakaryocytes.","date":"1995","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7559813","citation_count":29,"is_preprint":false},{"pmid":"33280236","id":"PMC_33280236","title":"HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3.","date":"2020","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33280236","citation_count":28,"is_preprint":false},{"pmid":"17656464","id":"PMC_17656464","title":"Transforming growth factor-beta blocks inhibin binding to different target cell types in a context-dependent manner through dual mechanisms involving betaglycan.","date":"2007","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17656464","citation_count":28,"is_preprint":false},{"pmid":"31409900","id":"PMC_31409900","title":"Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31409900","citation_count":27,"is_preprint":false},{"pmid":"30382077","id":"PMC_30382077","title":"Plau and Tgfbr3 are YAP-regulated genes that promote keratinocyte proliferation.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30382077","citation_count":27,"is_preprint":false},{"pmid":"21533152","id":"PMC_21533152","title":"Betaglycan is required for the establishment of nephron endowment in the mouse.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21533152","citation_count":27,"is_preprint":false},{"pmid":"14557487","id":"PMC_14557487","title":"Expression of betaglycan, an inhibin coreceptor, in normal human ovaries and ovarian sex cord-stromal tumors and its regulation in cultured human granulosa-luteal cells.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14557487","citation_count":26,"is_preprint":false},{"pmid":"37941530","id":"PMC_37941530","title":"Exosomes Derived from E2F1-/- Adipose-Derived Stem Cells Promote Skin Wound Healing via miR-130b-5p/TGFBR3 Axis.","date":"2023","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/37941530","citation_count":24,"is_preprint":false},{"pmid":"23322721","id":"PMC_23322721","title":"Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.","date":"2013","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23322721","citation_count":24,"is_preprint":false},{"pmid":"40011426","id":"PMC_40011426","title":"Structures of TGF-β with betaglycan and signaling receptors reveal mechanisms of complex assembly and signaling.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40011426","citation_count":23,"is_preprint":false},{"pmid":"27784788","id":"PMC_27784788","title":"Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27784788","citation_count":23,"is_preprint":false},{"pmid":"21167215","id":"PMC_21167215","title":"The type III TGF-β receptor betaglycan transmembrane-cytoplasmic domain fragment is stable after ectodomain cleavage and is a substrate of the intramembrane protease γ-secretase.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21167215","citation_count":23,"is_preprint":false},{"pmid":"32471132","id":"PMC_32471132","title":"The Tumor Suppressor TGFBR3 Blocks Lymph Node Metastasis in Head and Neck Cancer.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32471132","citation_count":22,"is_preprint":false},{"pmid":"16613887","id":"PMC_16613887","title":"Mutational analysis of the betaglycan gene-coding region in susceptibility for ovarian failure.","date":"2006","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16613887","citation_count":22,"is_preprint":false},{"pmid":"10384983","id":"PMC_10384983","title":"A regulatory role of fibroblast growth factor in the expression of decorin, biglycan, betaglycan and syndecan in osteoblasts from patients with Crouzon's syndrome.","date":"1999","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10384983","citation_count":22,"is_preprint":false},{"pmid":"36180862","id":"PMC_36180862","title":"LncRNA H19 alleviates sepsis-induced acute lung injury by regulating the miR-107/TGFBR3 axis.","date":"2022","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36180862","citation_count":21,"is_preprint":false},{"pmid":"35310542","id":"PMC_35310542","title":"Promoter Hypomethylation of TGFBR3 as a Risk Factor of Alzheimer's Disease: An Integrated Epigenomic-Transcriptomic Analysis.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35310542","citation_count":21,"is_preprint":false},{"pmid":"38438372","id":"PMC_38438372","title":"Cancer associated fibroblasts-derived SULF1 promotes gastric cancer metastasis and CDDP resistance through the TGFBR3-mediated TGF-β signaling pathway.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38438372","citation_count":21,"is_preprint":false},{"pmid":"39092729","id":"PMC_39092729","title":"The Role of TGFBR3 in the Development of Lung Cancer.","date":"2024","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/39092729","citation_count":20,"is_preprint":false},{"pmid":"31648935","id":"PMC_31648935","title":"A Tale of Two Proteins: Betaglycan, IGSF1, and the Continuing Search for the Inhibin B Receptor.","date":"2019","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/31648935","citation_count":19,"is_preprint":false},{"pmid":"26277894","id":"PMC_26277894","title":"Retinoic acid enhances lactoferrin-induced IgA responses by increasing betaglycan expression.","date":"2015","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26277894","citation_count":19,"is_preprint":false},{"pmid":"29979612","id":"PMC_29979612","title":"The t(1;10)(p22;q24) TGFBR3/MGEA5 Translocation in Pleomorphic Hyalinizing Angiectatic Tumor, Myxoinflammatory Fibroblastic Sarcoma, and Hemosiderotic Fibrolipomatous Tumor.","date":"2018","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29979612","citation_count":19,"is_preprint":false},{"pmid":"30598510","id":"PMC_30598510","title":"TGF-β2 uses the concave surface of its extended finger region to bind betaglycan's ZP domain via three residues specific to TGF-β and inhibin-α.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30598510","citation_count":19,"is_preprint":false},{"pmid":"25128652","id":"PMC_25128652","title":"Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFκB-mediated induction of MMP2.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25128652","citation_count":18,"is_preprint":false},{"pmid":"34369033","id":"PMC_34369033","title":"SNHG5 protects chondrocytes in interleukin-1β-stimulated osteoarthritis via regulating miR-181a-5p/TGFBR3 axis.","date":"2021","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34369033","citation_count":18,"is_preprint":false},{"pmid":"34162229","id":"PMC_34162229","title":"Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome.","date":"2021","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34162229","citation_count":18,"is_preprint":false},{"pmid":"20813352","id":"PMC_20813352","title":"Synthesis of the glycosaminoglycan-protein linkage tetraosyl peptide moieties of betaglycan, which serve as a hexosamine acceptor for enzymatic glycosyl transfer.","date":"2010","source":"Carbohydrate research","url":"https://pubmed.ncbi.nlm.nih.gov/20813352","citation_count":18,"is_preprint":false},{"pmid":"23835618","id":"PMC_23835618","title":"Dual role of TGFBR3 in bladder cancer.","date":"2013","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23835618","citation_count":17,"is_preprint":false},{"pmid":"19524135","id":"PMC_19524135","title":"Reducing betaglycan expression by RNA interference (RNAi) attenuates inhibin bioactivity in LbetaT2 gonadotropes.","date":"2009","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19524135","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55243,"output_tokens":9221,"usd":0.152022,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19497,"output_tokens":5551,"usd":0.11813,"stage2_stop_reason":"end_turn"},"total_usd":0.270152,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Betaglycan (TGFBR3) presents TGF-β directly to the type II signaling receptor kinase subunit, forming a high-affinity ternary complex. Membrane betaglycan increases TGF-β binding to the signaling receptor and eliminates biological differences between TGF-β isoforms.\",\n      \"method\": \"Receptor binding assays, crosslinking, cell-based functional assays with overexpression\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays, functional overexpression, replicated across multiple labs subsequently\",\n      \"pmids\": [\"8391934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Betaglycan is a membrane-anchored proteoglycan with an extracellular domain bearing GAG attachment sites; its transmembrane and cytoplasmic domains share homology with endoglin. The ectodomain can be shed as a soluble proteoglycan. GAG chains are dispensable for TGF-β binding to the core protein.\",\n      \"method\": \"cDNA cloning, sequencing, domain analysis, biochemical characterization\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — primary structure determination with functional validation; foundational structural paper replicated widely\",\n      \"pmids\": [\"1657406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"TGF-β binds to the NH2-terminal endoglin-related region of betaglycan. GAG attachment sites are Ser535 and Ser546; their mutation prevents GAG attachment but does not affect TGF-β binding or presentation. Membrane anchorage is required for TGF-β presentation to receptor II. Soluble betaglycan acts as a potent inhibitor (antagonist) of TGF-β binding to membrane receptors, particularly TGF-β2.\",\n      \"method\": \"Site-directed mutagenesis, deletion mutant analysis, binding assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis with multiple deletion constructs, functional assays; foundational mechanism paper\",\n      \"pmids\": [\"8106553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Betaglycan functions as an inhibin co-receptor with ActRII. Betaglycan binds inhibin with high affinity, enhances inhibin binding in cells co-expressing ActRII and betaglycan, and forms crosslinked ternary complexes with recombinant and endogenous betaglycan and ActRII. Betaglycan confers inhibin sensitivity to otherwise poorly responsive cell lines, enabling inhibin antagonism of activin signaling.\",\n      \"method\": \"Crosslinking assays, co-immunoprecipitation, cell-based functional assays, overexpression\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding and functional assays, multiple orthogonal methods, widely replicated\",\n      \"pmids\": [\"10746731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Betaglycan exists in both membrane-bound and soluble forms. The membrane-bound form is hydrophobic and associates with liposomes; soluble forms lack a membrane anchor. Both forms carry chondroitin sulfate and/or heparan sulfate GAG chains on a 100–120 kDa core protein.\",\n      \"method\": \"Biochemical characterization, liposome association assay, affinity labeling\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical characterization with multiple orthogonal methods; foundational paper\",\n      \"pmids\": [\"2592419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Betaglycan binds basic FGF (bFGF) via its heparan sulfate chains (separate domain from TGF-β binding via the core protein). In osteoblasts, bFGF selectively reduces the heparan sulfate GAG content of betaglycan without affecting chondroitin sulfate or core protein size.\",\n      \"method\": \"Affinity binding assays, metabolic labeling, GAG analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding measurements with domain-specific analysis; replicated concept of dual-domain binding\",\n      \"pmids\": [\"1556106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Betaglycan ectodomain contains two independent ligand-binding domains: the endoglin-related (membrane-distal) region and the uromodulin-related (membrane-proximal) region. Only the endoglin-related region mediates TGF-β presentation to TβRII. Inhibin A binding resides specifically in the uromodulin-related region. Both regions independently mediate Smad2 phosphorylation.\",\n      \"method\": \"Deletion mutagenesis, binding assays, Smad2 phosphorylation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis with functional domain mapping, multiple readouts\",\n      \"pmids\": [\"11278442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In LLC-PK1 renal epithelial cells (which lack endogenous betaglycan), betaglycan expression inhibits TGF-β signaling (Smad2/3 phosphorylation, reporter activity, collagen production) by preventing association between type I and type II TGF-β receptors. This inhibitory function depends on the molecular weight of the GAG chains; a GAG-deficient betaglycan mutant does not inhibit signaling or type I/type II receptor association in these cells.\",\n      \"method\": \"Reporter assay, thymidine incorporation, collagen production, Smad phosphorylation, co-immunoprecipitation of receptor complexes, GAG mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional assays with mechanistic mutant analysis\",\n      \"pmids\": [\"11668175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Betaglycan shedding is mediated by MT1-MMP (membrane type-1 matrix metalloprotease), which generates a 90 kDa soluble fragment (sBG-90) in a TIMP-2-sensitive manner. MT3-MMP can also generate this fragment. Pervanadate (a tyrosine phosphatase inhibitor) induces shedding. The shed sBG-90 retains higher affinity for TGF-β2 than TGF-β1.\",\n      \"method\": \"MT-MMP overexpression, metalloprotease inhibitor treatment, Western blot, binding competition assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MT1-MMP overexpression in COS-1 cells confirming mechanism, multiple MT-MMP comparisons, two orthogonal methods\",\n      \"pmids\": [\"14672946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Plasmin selectively cleaves betaglycan on the cell surface, releasing a 60 kDa TGF-β complex into the medium and reducing TGF-β binding to cellular betaglycan. Type I and type II TGF-β receptors are not plasmin substrates. Conditioned medium from plasmin-treated cells contains increased active TGF-β.\",\n      \"method\": \"Affinity labeling, SDS-PAGE, bioassay for TGF-β activity\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct cell-based cleavage assay with functional readout, single lab\",\n      \"pmids\": [\"8068006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Soluble betaglycan requires both its N-terminal (45 kDa) and C-terminal (55 kDa) domains tethered together for high-affinity TGF-β binding (low nM Kd). Isolated domains bind TGF-β with 1–2 orders of magnitude lower affinity and have severely diminished ability to neutralize TGF-β activity. Plasmin cleaves the linker between domains, separating them and inactivating TGF-β neutralizing activity.\",\n      \"method\": \"Plasmin digestion, N-terminal sequencing, surface plasmon resonance, recombinant domain expression, TGF-β neutralization assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with SPR quantification and domain mutagenesis; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"19842711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Distinct and partially overlapping binding sites for inhibin and TGF-β reside within amino acids 591–700 of betaglycan's ZP domain. Mutation of Val614 to Tyr abolishes both inhibin and TGF-β binding to this domain. Full-length betaglycan V614Y retains TGF-β binding via the N-terminal domain but cannot bind inhibin A or mediate inhibin antagonism of activin signaling, functionally separating these co-receptor actions.\",\n      \"method\": \"Mutagenesis, binding assays, functional activin/inhibin reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis with functional validation; single lab, multiple orthogonal assays\",\n      \"pmids\": [\"16621788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure (2.0 Å) of betaglycan ZP-C domain reveals an immunoglobulin-like fold. The EHP region is integral to the ZP-C domain. The AB loop and convex surface pocket are implicated in TGF-β ligand binding. Betaglycan lacks the maturation cleavage site present in polymerizing ZP proteins, explaining its non-polymerizing behavior.\",\n      \"method\": \"X-ray crystallography at 2.0 Å resolution\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — high-resolution crystal structure with structural analysis; single study\",\n      \"pmids\": [\"21402931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Betaglycan binds TGF-β homodimers with 1:1 stoichiometry and modestly potentiates TβRII binding. Betaglycan must be displaced to allow TβRI to bind. These findings suggest betaglycan concentrates TGF-β2 on the cell surface and promotes TβRII binding via membrane localization and allostery, with TβRI recruitment driving displacement of betaglycan to complete signaling complex formation.\",\n      \"method\": \"Surface plasmon resonance, isothermal titration calorimetry, size-exclusion chromatography\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — three orthogonal biophysical methods defining stoichiometry and mechanism; single lab\",\n      \"pmids\": [\"27951653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Cryo-EM/structural analysis of TGF-β bound to betaglycan and signaling receptors (TGFBR1 and TGFBR2) reveals the structural basis for ligand selectivity and provides a structural explanation for the hand-off mechanism in which betaglycan is displaced as signaling receptors engage TGF-β. Binding interfaces differ from those used by the related co-receptor endoglin, demonstrating evolutionary adaptation for ligand selectivity.\",\n      \"method\": \"Structural determination (cryo-EM/crystallography) of ternary complex\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct structure of betaglycan/TGF-β/signaling receptor complex; single study but high-resolution structural method\",\n      \"pmids\": [\"40011426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NMR titrations and SPR measurements map the betaglycan ZP-C domain binding site on TGF-β2 to the inner concave surface of its extended finger region, involving residues Ile-92, Lys-97, and Glu-99 that are specific to TGF-β isoforms and InhA α-subunit but absent from other TGF-β family members such as BMP-2.\",\n      \"method\": \"Methyl-labeled NMR titrations, surface plasmon resonance with TGF-β2 mutant variants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR and SPR with mutagenesis defining binding interface; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"30598510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Overexpression of betaglycan in rat myoblasts enhances TGF-β-mediated growth inhibition and PAI-1 expression; betaglycan specifically increases TGF-β binding to the type II receptor. Analysis of endoglin/betaglycan chimeric proteins shows that the extracellular domain governs functional differences between the two co-receptors.\",\n      \"method\": \"Overexpression in myoblasts, 125I-TGF-β crosslinking, PAI-1 reporter assay, chimeric protein analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional overexpression with ligand binding and reporter assays; chimeric domain analysis; single lab\",\n      \"pmids\": [\"9830054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Inhibin-A binding to betaglycan causes clathrin-independent endocytic internalization of betaglycan, thereby reducing available TGF-β2 binding sites on the cell surface and antagonizing TGF-β2 signaling. This is distinct from the mechanism by which TGF-β ligands induce betaglycan internalization.\",\n      \"method\": \"Cell surface binding assays, internalization assays, functional signaling readouts in adrenocortical cells\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic cell-based assays demonstrating internalization and functional consequence; single lab\",\n      \"pmids\": [\"20160125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Betaglycan overexpression via adenoviral expression induces TGF-β target gene expression (p3TP-Lux, CTGF, fibronectin) and inhibits myogenin expression in the absence of exogenous TGF-β (ligand-independent signaling). This effect requires the cytoplasmic domain of betaglycan and is independent of Smad2 phosphorylation but involves p38 MAP kinase phosphorylation.\",\n      \"method\": \"Adenoviral overexpression, reporter assays, TGF-β neutralizing antibodies, p38 inhibitor (SB239063), Western blot for phospho-p38 and phospho-Smad2\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple reporter assays with ligand-blocking controls and pharmacological inhibition; single lab\",\n      \"pmids\": [\"16413747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The transmembrane-cytoplasmic fragment remaining after betaglycan ectodomain shedding is stable in cells and serves as a substrate for γ-secretase intramembrane proteolysis. γ-Secretase inhibition stabilizes the fragment. Expression of this fragment or γ-secretase inhibition blunts TGF-β2 signaling in HepG2 cells.\",\n      \"method\": \"γ-Secretase inhibitor treatment, ectodomain shedding inhibitor (TAPI-2), Western blot, TGF-β2 signaling reporter\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibitor assays with functional signaling readout; single lab\",\n      \"pmids\": [\"21167215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Glucocorticoids (dexamethasone and others) upregulate Tgfbr3 expression in lung fibroblasts. Tgfbr3 acts as a 'switch' that blunts Tgfbr1/Smad2/3 signaling and potentiates Acvrl1/Smad1 signaling. Dexamethasone acts synergistically with TGF-β to drive myofibroblast differentiation through Smad1-dependent processes in an in vivo mouse model.\",\n      \"method\": \"Reporter assays, Western blot for phospho-Smad1 and phospho-Smad2/3, primary cell culture experiments, in vivo mouse dexamethasone treatment, RNAi knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell types and in vivo validation; single lab\",\n      \"pmids\": [\"24347165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Tgfbr3 knockout mice exhibit defects in seminiferous cord formation and compromised fetal Leydig cell function (reduced expression of Insl3, Cyp17a1, Cyp11a1, Star, Hsd3b1) without changes in Leydig cell counts, indicating that betaglycan is required for fetal testis structure and Leydig cell endocrine function.\",\n      \"method\": \"Tgfbr3 knockout mouse analysis, immunohistochemistry, quantitative RT-PCR, whole-mount in situ hybridization, morphometric analysis\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with multiple cellular and molecular readouts; single lab\",\n      \"pmids\": [\"19696014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Betaglycan heterozygous mice display augmented nephron number and accelerated ureteric branching, while betaglycan null mice exhibit renal hypoplasia and reduced nephron number. Gene expression analysis links betaglycan dosage to regulation of Bmp4, Pax2, Eya1, Gdnf, Ret, Wnt4, and Wt1 expression in developing kidneys.\",\n      \"method\": \"Stereological analysis of embryonic/adult kidneys, quantitative RT-PCR, heterozygous and null mouse analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic dosage series with morphometric and molecular endpoints; single lab\",\n      \"pmids\": [\"21533152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Endogenous betaglycan is required for high-potency inhibin antagonism in rat anterior pituitary gonadotropes. Betaglycan knockdown (siRNA) or immunoneutralization with anti-betaglycan IgG each decreased the potency of inhibin antagonism of activin-induced FSH secretion by more than 1000-fold, without affecting activin responsiveness.\",\n      \"method\": \"siRNA knockdown, immunoneutralization, primary pituitary gonadotrope culture, FSH secretion assay\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent loss-of-function approaches (siRNA + antibody) with functional FSH secretion readout\",\n      \"pmids\": [\"19372236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TGFBR3 functions as an obligate inhibin A co-receptor in murine pituitary gonadotropes in vivo, but is not required for inhibin B suppression of FSH. Conditional knockout of Tgfbr3 in gonadotropes impairs inhibin A but not inhibin B suppression of FSH synthesis in cultured pituitaries.\",\n      \"method\": \"Conditional gonadotrope-specific Tgfbr3 knockout mice, pituitary cell culture, FSH assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific functional readout; single lab, in vivo genetic model\",\n      \"pmids\": [\"30364975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TGFBR3 regulates canonical Wnt3a signaling independently of its TGF-β co-receptor function. Heparan sulfate GAG chains on TGFBR3 sequester Wnt3a and inhibit Wnt signaling, while chondroitin sulfate GAG chains promote Wnt3a signaling. The balance of these modifications determines the net effect on Wnt pathway activation.\",\n      \"method\": \"Overexpression/knockdown, luciferase reporter assays for Wnt signaling, GAG-deficient and sulfation mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple constructs with different GAG modifications, reporter assays; single lab\",\n      \"pmids\": [\"27784788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The inhibin A binding epitope on betaglycan involves residues Tyr50, Val108, Thr111, Ser112, Phe118, Lys119, and Tyr120 of the inhibin α-subunit. Simultaneous mutation of Thr111, Ser112, and Tyr120 to alanine abolishes betaglycan binding and renders inhibin A unable to suppress activin-induced FSH release from pituitary cells.\",\n      \"method\": \"Mutagenesis of inhibin A, binding assays, pituitary cell FSH bioassay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of ligand binding interface with functional FSH suppression readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18397882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of TGFBR3 in clear-cell renal cell carcinoma enhances cell migration through TGF-β-independent activation of FAK-PI3K signaling with increased lamellipodium formation, and also enhances TGF-β2-dependent reduction in the ALDH-positive cancer-initiating cell population. Orthotopic inoculation showed that low TGFBR3 enhances primary tumor formation and lung metastasis.\",\n      \"method\": \"Orthotopic mouse inoculation, cell migration assays, ALDH flow cytometry, signaling pathway inhibitors\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo orthotopic model with mechanistic pathway analysis; single lab\",\n      \"pmids\": [\"29391598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Betaglycan loss in MSCs augments TGF-β signaling, blocks the MSC-osteoblast differentiation program, and is required for prostate cancer-induced osteogenesis in vivo. Mechanistically, betaglycan loss induces >60-fold increase in Wnt5a expression, activating canonical Wnt signaling; Wnt5a neutralizing antibody rescues osteogenic gene expression in betaglycan-ablated MSCs.\",\n      \"method\": \"Betaglycan knockdown in MSCs, osteoblast differentiation assays, in vivo xenograft osteogenesis, gene expression analysis, Wnt5a neutralizing antibody rescue\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo model with mechanistic rescue experiment; single lab\",\n      \"pmids\": [\"31409900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TGFBR3 forms a complex with β-arrestin 2 and IκBα. Overexpression of TGFBR3 decreases phospho-p65 (NF-κB) and increases IκBα expression in oral cancer cells; these effects are abolished by β-arrestin 2 knockdown.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, siRNA knockdown\",\n      \"journal\": \"Cell adhesion & migration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP with functional knockdown rescue; single lab\",\n      \"pmids\": [\"29130787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Betaglycan suppresses NFκB activity in granulosa tumor cells, reduces basal and TGF-β2-stimulated NFκB activity, and reduces cell viability in concert with NFκB inhibition. ERK1/2 activation converges the NFκB, SMAD3, and TGF-β2/betaglycan pathways. SMAD3 and NFκB form a positive feedback loop; betaglycan expression disrupts this loop.\",\n      \"method\": \"NFκB reporter assay, SMAD2/3 knockdown, pharmacological NFκB inhibition, cell viability assay, overexpression of betaglycan in GCT cell lines\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway intervention assays with functional readout; confirmed in two cell lines\",\n      \"pmids\": [\"23322721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Granzyme B cleaves soluble betaglycan as an extracellular substrate, releasing active TGF-β1 sequestered by betaglycan. Released TGF-β1 retains bioactivity as demonstrated by Smad3 phosphorylation in smooth muscle cells.\",\n      \"method\": \"In vitro protease cleavage assay, TGF-β1 cytokine release assay, Smad3 phosphorylation Western blot\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro cleavage with functional TGF-β1 activity readout; single lab\",\n      \"pmids\": [\"22479366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Lactoferrin directly binds betaglycan (TGFBR3) and induces formation of TβRIII/TβRII/TβRI complex, leading to TβRI and Smad3 phosphorylation and IgA/IgG2b isotype switching in B cells. This represents a ligand-mediated mechanism for betaglycan to initiate canonical TGF-β signaling.\",\n      \"method\": \"Binding assays (lactoferrin-betaglycan direct interaction), co-immunoprecipitation of receptor complex, Western blot for Smad3 phosphorylation, B cell Ig class switching assays\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding plus complex formation plus functional signaling readout; single lab\",\n      \"pmids\": [\"25492477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TGF-β competes with inhibin A for binding to betaglycan on gonadotrope cells, reducing inhibin's ability to antagonize activin-induced FSH synthesis. TGF-β1 and TGF-β2 competed with 125I-inhibin for betaglycan binding in crosslinking experiments, suggesting TGF-β can counter inhibin action by occupying the shared betaglycan binding site.\",\n      \"method\": \"Radiolabeled inhibin A competition binding, immunoprecipitation of crosslinked receptor complexes, activin-responsive reporter assays in LβT2 cells\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal competition binding with functional reporter assay; single lab\",\n      \"pmids\": [\"12456797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Endoglin associates with betaglycan on human microvascular endothelial cells in a ligand-dependent and ligand-independent manner to form higher-order complexes that also include type I and/or type II TGF-β receptors.\",\n      \"method\": \"Co-immunoprecipitation, affinity labeling with radiolabeled TGF-β\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP and affinity labeling in endogenous cell context; single lab\",\n      \"pmids\": [\"10951214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Endoglin forms a heteromeric complex with betaglycan on human chondrocytes in both a ligand-independent and ligand-dependent manner, independently of the type II TGF-β receptor.\",\n      \"method\": \"Co-immunoprecipitation in absence of TGF-β and after affinity labeling with radiolabeled TGF-β\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP with two conditions (ligand-dependent and independent); single lab\",\n      \"pmids\": [\"12568406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TGF-β1 pretreatment of Leydig (TM3) and Sertoli (TM4) cells suppresses betaglycan mRNA levels by 46–73%, reducing subsequent inhibin A binding and betaglycan affinity labeling. This represents an indirect mechanism by which TGF-β blocks inhibin binding via downregulation of betaglycan. In cells lacking TβRII, only direct ligand competition is operational.\",\n      \"method\": \"RT-PCR, 125I-inhibin A affinity labeling, betaglycan mRNA quantification\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell lines, quantified binding and expression changes; single lab\",\n      \"pmids\": [\"17656464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TGFBR3 is identified as a target of let-7 microRNAs; induction of Tgfbr3 in cardiomyocytes causes apoptosis via p38 MAPK activation following myocardial infarction. AAV9-mediated let-7 overexpression reduced cardiomyocyte apoptosis, cardiac hypertrophy, and improved ejection fraction.\",\n      \"method\": \"AAV9-mediated microRNA overexpression/knockdown in mice, MI model, apoptosis assays, Western blot for p38 MAPK activation\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo AAV-mediated gain/loss-of-function with functional cardiac readouts; single lab\",\n      \"pmids\": [\"31401194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cancer-associated fibroblast-secreted SULF1 binds TGFBR3 on gastric cancer cell membranes, interfering with TGF-β1/TGFBR3 interaction and subsequently activating downstream TGF-β signaling to promote metastasis and CDDP resistance.\",\n      \"method\": \"Co-immunoprecipitation/binding assays, functional migration and drug resistance assays, in vitro cancer-fibroblast co-culture system\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, binding and functional assays but mechanistic detail limited in abstract\",\n      \"pmids\": [\"38438372\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TGFBR3 (betaglycan) is a membrane-anchored heparan sulfate/chondroitin sulfate proteoglycan that functions as a multi-ligand co-receptor: it presents TGF-β (especially TGF-β2) to the type II signaling receptor by forming a high-affinity ternary complex (requiring membrane anchorage and its N-terminal endoglin-related domain), acts as a high-affinity inhibin A co-receptor via its C-terminal ZP domain to potentiate inhibin antagonism of activin signaling, and can modulate Wnt and NF-κB pathways independently of TGF-β; its ectodomain is shed by MT1-MMP and further processed by γ-secretase, converting it from a TGF-β enhancer to an antagonist; depending on cell context and GAG chain composition, betaglycan can either enhance or inhibit TGF-β signaling by controlling type I/type II receptor complex formation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TGFBR3 (betaglycan) is a membrane-anchored heparan sulfate/chondroitin sulfate proteoglycan that functions as a multi-ligand co-receptor controlling the access of TGF-\\u03b2 superfamily ligands to their signaling receptors [#0, #1]. It captures TGF-\\u03b2\\u2014including isoforms that bind the signaling receptors poorly\\u2014through its N-terminal endoglin-related domain and presents it to the type II receptor (T\\u03b2RII), forming a high-affinity ternary complex that requires membrane anchorage and equalizes the activity of TGF-\\u03b2 isoforms [#0, #2, #6]; subsequent recruitment of T\\u03b2RI drives displacement of betaglycan to complete the signaling complex, a hand-off mechanism resolved structurally [#13, #14]. High-affinity ligand binding depends on cooperation between its N-terminal endoglin-related and C-terminal zona pellucida (ZP) domains tethered together [#10, #12]. Through the ZP domain it acts as an obligate high-affinity inhibin A co-receptor with ActRII, conferring inhibin sensitivity and enabling inhibin antagonism of activin signaling\\u2014a function genetically separable from TGF-\\u03b2 presentation and required in vivo for inhibin A suppression of pituitary FSH [#3, #11, #23, #24]. Betaglycan's net effect on TGF-\\u03b2 signaling is context-dependent: depending on cell type and GAG composition it either enhances signaling or inhibits it by blocking type I/type II receptor association, the latter requiring intact GAG chains [#7, #16]. Its ectodomain is shed by MT1-MMP/MT3-MMP to yield a soluble TGF-\\u03b2-neutralizing antagonist, and the residual membrane stub is cleaved by \\u03b3-secretase, converting betaglycan from a signaling enhancer into an antagonist [#8, #19]. Independently of TGF-\\u03b2, betaglycan modulates canonical Wnt signaling via its GAG chains and suppresses NF-\\u03baB activity through a \\u03b2-arrestin 2/I\\u03baB\\u03b1 complex [#25, #29, #30]. Loss-of-function in mice establishes betaglycan as required for fetal testis cord formation and Leydig cell endocrine function and for proper kidney nephron number and ureteric branching [#21, #22].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Established that betaglycan exists as both membrane-bound and soluble GAG-bearing proteoglycan forms, defining the structural basis for its dual cell-surface and soluble functions.\",\n      \"evidence\": \"Biochemical characterization, liposome association and affinity labeling\",\n      \"pmids\": [\"2592419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the ligand-presentation function\", \"GAG contribution to function not yet tested\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"cDNA cloning revealed the domain architecture\\u2014extracellular GAG-bearing ectodomain with transmembrane/cytoplasmic homology to endoglin\\u2014and showed GAG chains are dispensable for TGF-\\u03b2 binding to the core protein, separating ligand binding from glycosylation.\",\n      \"evidence\": \"cDNA cloning, sequencing and domain analysis\",\n      \"pmids\": [\"1657406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of cytoplasmic domain unresolved\", \"Mechanism of presentation to signaling receptors not addressed\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrated the core co-receptor mechanism: betaglycan presents TGF-\\u03b2 to the type II receptor in a high-affinity ternary complex and eliminates isoform-specific differences in signaling potency.\",\n      \"evidence\": \"Receptor binding/crosslinking and cell-based functional assays with overexpression\",\n      \"pmids\": [\"8391934\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the ternary complex not defined\", \"How T\\u03b2RI is recruited unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Mapped TGF-\\u03b2 binding to the N-terminal endoglin-related region, localized GAG attachment sites (Ser535/Ser546), and showed membrane anchorage is required for presentation while soluble betaglycan acts as a TGF-\\u03b2 antagonist\\u2014defining the enhancer-versus-antagonist duality.\",\n      \"evidence\": \"Site-directed and deletion mutagenesis with binding assays; plasmin cleavage assays\",\n      \"pmids\": [\"8106553\", \"8068006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Second ligand-binding domain not yet defined\", \"Physiological proteases controlling shedding unknown\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Showed dual-domain binding capacity\\u2014bFGF binds heparan sulfate chains independently of TGF-\\u03b2 binding to the core\\u2014establishing betaglycan as a multi-ligand proteoglycan.\",\n      \"evidence\": \"Affinity binding, metabolic labeling and GAG analysis in osteoblasts\",\n      \"pmids\": [\"1556106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling consequence of bFGF binding not established\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified betaglycan as a high-affinity inhibin co-receptor that partners with ActRII to confer inhibin sensitivity, extending its role beyond TGF-\\u03b2 to activin antagonism.\",\n      \"evidence\": \"Crosslinking, co-IP and functional cell assays with overexpression\",\n      \"pmids\": [\"10746731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibin-binding domain not localized\", \"In vivo physiological requirement untested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved a two-domain ligand architecture (endoglin-related for TGF-\\u03b2 presentation, uromodulin/ZP-related for inhibin A) and showed that in cells lacking endogenous betaglycan its expression inhibits TGF-\\u03b2 signaling by preventing type I/type II receptor association in a GAG-dependent manner.\",\n      \"evidence\": \"Deletion mutagenesis, Smad2 phosphorylation, receptor co-IP and GAG mutant analysis\",\n      \"pmids\": [\"11278442\", \"11668175\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why context determines enhancement vs inhibition not fully resolved\", \"Role of GAG chain size mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified MT1-MMP/MT3-MMP as the proteases that shed the betaglycan ectodomain, defining the regulated step that generates the soluble TGF-\\u03b2 antagonist.\",\n      \"evidence\": \"MT-MMP overexpression, metalloprotease inhibition and binding assays\",\n      \"pmids\": [\"14672946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological triggers of shedding in vivo unclear\", \"Fate of the membrane stub not addressed here\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Functionally separated betaglycan's co-receptor roles by mapping overlapping inhibin/TGF-\\u03b2 sites in the ZP domain (V614Y abolishes both) and identifying ligand-independent signaling requiring the cytoplasmic domain via p38 MAPK.\",\n      \"evidence\": \"Mutagenesis with functional reporters; adenoviral overexpression with p38 inhibitor\",\n      \"pmids\": [\"16621788\", \"16413747\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cytoplasmic-domain signaling partners undefined\", \"Relationship between p38 axis and canonical Smad signaling unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the inhibin \\u03b1-subunit residues forming the betaglycan-binding epitope, linking a precise molecular interface to FSH regulation.\",\n      \"evidence\": \"Inhibin A mutagenesis, binding assays and pituitary FSH bioassay\",\n      \"pmids\": [\"18397882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reciprocal betaglycan residues not all defined here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed that high-affinity soluble betaglycan requires both N- and C-terminal domains tethered together and that endogenous betaglycan is functionally required for high-potency inhibin antagonism in gonadotropes.\",\n      \"evidence\": \"SPR with recombinant domains and plasmin digestion; siRNA and immunoneutralization in pituitary cells; Tgfbr3-null mouse testis analysis\",\n      \"pmids\": [\"19842711\", \"19372236\", \"19696014\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural picture of two-domain ligand engagement still indirect\", \"Tissue-specific downstream effectors incompletely mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified the post-shedding steps\\u2014\\u03b3-secretase processing of the membrane stub and inhibin-A-induced clathrin-independent internalization\\u2014that convert betaglycan into a TGF-\\u03b2 antagonist and reduce surface ligand sites.\",\n      \"evidence\": \"\\u03b3-secretase/shedding inhibitors with signaling reporters; cell-surface internalization assays\",\n      \"pmids\": [\"21167215\", \"20160125\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream fate/function of the intracellular fragment unknown\", \"Internalization machinery not molecularly defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided the high-resolution crystal structure of the ZP-C domain (Ig-like fold, integral EHP region) and genetic dosage analysis linking betaglycan levels to kidney nephron number and branching gene programs.\",\n      \"evidence\": \"X-ray crystallography at 2.0 \\u00c5; stereological and qRT-PCR analysis of heterozygous/null mouse kidneys\",\n      \"pmids\": [\"21402931\", \"21533152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the full ligand-bound complex not yet available\", \"Mechanism connecting dosage to branching genes correlative\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined the biophysical hand-off model\\u2014betaglycan binds TGF-\\u03b2 1:1, modestly potentiates T\\u03b2RII binding, and must be displaced for T\\u03b2RI to engage\\u2014and uncovered a GAG-dependent, TGF-\\u03b2-independent role in Wnt3a signaling.\",\n      \"evidence\": \"SPR/ITC/SEC stoichiometry; Wnt luciferase reporters with GAG/sulfation mutants\",\n      \"pmids\": [\"27951653\", \"27784788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural geometry of displacement not directly observed at this stage\", \"Wnt-modulating GAG mechanism not resolved in vivo\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the TGF-\\u03b22 surface engaged by the betaglycan ZP-C domain and established betaglycan as an obligate inhibin A (but not inhibin B) co-receptor in gonadotropes in vivo.\",\n      \"evidence\": \"NMR/SPR interface mapping with TGF-\\u03b22 mutants; conditional gonadotrope Tgfbr3 knockout with FSH assay\",\n      \"pmids\": [\"30598510\", \"30364975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of inhibin A vs inhibin B discrimination unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established context-specific tumor and tissue roles: betaglycan loss promotes renal carcinoma migration/metastasis via FAK-PI3K and prostate-cancer-induced osteogenesis via Wnt5a, and let-7-driven TGFBR3 induction promotes cardiomyocyte apoptosis after infarction.\",\n      \"evidence\": \"Orthotopic/xenograft mouse models, pathway inhibitors, Wnt5a-neutralization rescue, AAV9 microRNA modulation\",\n      \"pmids\": [\"29391598\", \"31409900\", \"31401194\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between betaglycan and FAK-PI3K not defined\", \"Disease relevance to human pathology correlative\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Provided the structural basis for the betaglycan-to-signaling-receptor hand-off and for ligand selectivity, showing interfaces distinct from endoglin.\",\n      \"evidence\": \"Cryo-EM/structural determination of TGF-\\u03b2/betaglycan/TGFBR1/TGFBR2 complex\",\n      \"pmids\": [\"40011426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics and kinetics of displacement in living membranes not captured\", \"GAG-chain contribution to the complex not structurally resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GAG chain composition, ectodomain shedding, and cell context are integrated to switch betaglycan between TGF-\\u03b2 enhancer and antagonist in specific tissues remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking GAG editing to context-dependent signaling output\", \"In vivo regulators of the enhancer/antagonist switch not identified\", \"Mendelian disease association not established in this corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 6, 13, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 3, 7, 23]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 32]},\n      {\"term_id\": \"GO:0008201\", \"supporting_discovery_ids\": [5, 25]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2, 4, 7]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 8, 10, 31]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 7, 13]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [21, 22]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [23, 24]}\n    ],\n    \"complexes\": [\n      \"TGF-\\u03b2/betaglycan/T\\u03b2RII/T\\u03b2RI ternary signaling complex\",\n      \"inhibin A/betaglycan/ActRII co-receptor complex\",\n      \"betaglycan/\\u03b2-arrestin 2/I\\u03baB\\u03b1 complex\"\n    ],\n    \"partners\": [\n      \"TGFBR2\",\n      \"TGFBR1\",\n      \"ACVR2A\",\n      \"ENG\",\n      \"ARRB2\",\n      \"NFKBIA\",\n      \"MMP14\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}